Publications by authors named "E Garcia-Gil"
Article Synopsis
- Lebrikizumab, a monoclonal antibody targeting interleukin-13, was studied for its effects on immune responses to non-live vaccines in adults with moderate-to-severe atopic dermatitis (AD).
- The phase 3, double-blind study involved randomizing patients to receive either lebrikizumab or a placebo, with the main focus on responses to tetanus and meningococcal vaccines after 16 weeks.
- Results indicated similar Tdap booster responses between both groups, but lebrikizumab patients showed a significantly higher rate of positive response to the meningococcal vaccine and better improvement in AD symptoms compared to the placebo group.
Regulatory T cells (Tregs) is a subtype of CD4+ T cells that produce an inhibitory action against effector cells. In the present work we interrogated genomic datasets to explore the transcriptomic profile of breast tumors with high expression of Tregs. Only 0.
View Article and Find Full Text PDFBackground: Pivotal phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its real-world effectiveness in SEA according to previous biologic use and key baseline characteristics important for treatment selection.
Methods: XALOC-1 is a large, multinational, retrospective, observational, real-world study programme of benralizumab in adults with SEA.
Background: CompEx Asthma, a composite end-point for asthma exacerbations, captures clinically relevant, diary-based acute worsening events (AWEs) (defined as deterioration in daily peak expiratory flow concurrent with deterioration in asthma symptoms and/or rescue therapy use) and severe exacerbations (SevEx) (defined by American Thoracic Society/European Respiratory Society guidelines). We hypothesised that CompEx and SevEx would show similar benralizumab treatment effects and correlations to blood eosinophil counts in patients with severe asthma.
Methods: This analysis of pooled 12-month data from two phase 3 studies included patients aged ≥16 years with severe, uncontrolled asthma who were randomised to benralizumab 30 mg or placebo.